KILLER IG-LIKE RECEPTOR (KIR) ANTIBODIES, FORMULATIONS, AND USES THEREOF
Inhibitory Killer lg-Like Receptors (KIRs) on NK cells inhibit the activation of NK cell cytotoxicity required to clear cancer cells and other diseased cells in a subject. An IgG4 isotype anti-KIR antibody (1-7F9) overcomes the KIR-mediated inhibition of NK cell activation and, thus, potentiates NK...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SVENSSON, ROZANA OVERGAARD, RUNE VIIG WAGTMANN, PETER ANDREAS NICOLAI REUMERT SVENDSEN, IVAN ALIFRANGIS, LENE HJORTH |
| description | Inhibitory Killer lg-Like Receptors (KIRs) on NK cells inhibit the activation of NK cell cytotoxicity required to clear cancer cells and other diseased cells in a subject. An IgG4 isotype anti-KIR antibody (1-7F9) overcomes the KIR-mediated inhibition of NK cell activation and, thus, potentiates NK cell-mediated cytotoxicity. The pharmacokinetics and pharmacodynamics of 1-7F9 is assessed in pre-clinical and clinical trials in order to determine a dosing frequency that is effective to potentiate NK cell cytotoxicity (i.e., modulate NK cells and/or treat cancer).
L'invention porte sur un nouvel anticorps anti-KIR isotype IgG4, sur de nouvelles formulations de celui-ci et d'autres anticorps anti-KIR IgG4, et sur des procédés d'utilisation de telles formulations. L'invention porte également sur des compositions, des formulations, des dosages et des régimes d'administration appropriés pour une activation des lymphocytes NK et des applications thérapeutiques d'anticorps anti-KIR, ainsi que sur des coffrets comprenant un ou plusieurs anticorps anti-KIR avec des instructions pour une utilisation dans le traitement du cancer. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA2675291C</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA2675291C</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA2675291C3</originalsourceid><addsrcrecordid>eNrjZPDw9vTxcQ1S8HTX9fH0dlUIcnV2DQjxD1LQ8PYM0lRw9AvxdPJ38XQN1lFw8w_yDfVxDPH09wPyHP1cFEKDXYMVQjxcg1z93XgYWNMSc4pTeaE0N4O8m2uIs4duakF-fGpxQWJyal5qSbyzo5GZuamRpaGzMWEVACHdK5I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>KILLER IG-LIKE RECEPTOR (KIR) ANTIBODIES, FORMULATIONS, AND USES THEREOF</title><source>esp@cenet</source><creator>SVENSSON, ROZANA ; OVERGAARD, RUNE VIIG ; WAGTMANN, PETER ANDREAS NICOLAI REUMERT ; SVENDSEN, IVAN ; ALIFRANGIS, LENE HJORTH</creator><creatorcontrib>SVENSSON, ROZANA ; OVERGAARD, RUNE VIIG ; WAGTMANN, PETER ANDREAS NICOLAI REUMERT ; SVENDSEN, IVAN ; ALIFRANGIS, LENE HJORTH</creatorcontrib><description>Inhibitory Killer lg-Like Receptors (KIRs) on NK cells inhibit the activation of NK cell cytotoxicity required to clear cancer cells and other diseased cells in a subject. An IgG4 isotype anti-KIR antibody (1-7F9) overcomes the KIR-mediated inhibition of NK cell activation and, thus, potentiates NK cell-mediated cytotoxicity. The pharmacokinetics and pharmacodynamics of 1-7F9 is assessed in pre-clinical and clinical trials in order to determine a dosing frequency that is effective to potentiate NK cell cytotoxicity (i.e., modulate NK cells and/or treat cancer).
L'invention porte sur un nouvel anticorps anti-KIR isotype IgG4, sur de nouvelles formulations de celui-ci et d'autres anticorps anti-KIR IgG4, et sur des procédés d'utilisation de telles formulations. L'invention porte également sur des compositions, des formulations, des dosages et des régimes d'administration appropriés pour une activation des lymphocytes NK et des applications thérapeutiques d'anticorps anti-KIR, ainsi que sur des coffrets comprenant un ou plusieurs anticorps anti-KIR avec des instructions pour une utilisation dans le traitement du cancer.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170523&DB=EPODOC&CC=CA&NR=2675291C$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170523&DB=EPODOC&CC=CA&NR=2675291C$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SVENSSON, ROZANA</creatorcontrib><creatorcontrib>OVERGAARD, RUNE VIIG</creatorcontrib><creatorcontrib>WAGTMANN, PETER ANDREAS NICOLAI REUMERT</creatorcontrib><creatorcontrib>SVENDSEN, IVAN</creatorcontrib><creatorcontrib>ALIFRANGIS, LENE HJORTH</creatorcontrib><title>KILLER IG-LIKE RECEPTOR (KIR) ANTIBODIES, FORMULATIONS, AND USES THEREOF</title><description>Inhibitory Killer lg-Like Receptors (KIRs) on NK cells inhibit the activation of NK cell cytotoxicity required to clear cancer cells and other diseased cells in a subject. An IgG4 isotype anti-KIR antibody (1-7F9) overcomes the KIR-mediated inhibition of NK cell activation and, thus, potentiates NK cell-mediated cytotoxicity. The pharmacokinetics and pharmacodynamics of 1-7F9 is assessed in pre-clinical and clinical trials in order to determine a dosing frequency that is effective to potentiate NK cell cytotoxicity (i.e., modulate NK cells and/or treat cancer).
L'invention porte sur un nouvel anticorps anti-KIR isotype IgG4, sur de nouvelles formulations de celui-ci et d'autres anticorps anti-KIR IgG4, et sur des procédés d'utilisation de telles formulations. L'invention porte également sur des compositions, des formulations, des dosages et des régimes d'administration appropriés pour une activation des lymphocytes NK et des applications thérapeutiques d'anticorps anti-KIR, ainsi que sur des coffrets comprenant un ou plusieurs anticorps anti-KIR avec des instructions pour une utilisation dans le traitement du cancer.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPDw9vTxcQ1S8HTX9fH0dlUIcnV2DQjxD1LQ8PYM0lRw9AvxdPJ38XQN1lFw8w_yDfVxDPH09wPyHP1cFEKDXYMVQjxcg1z93XgYWNMSc4pTeaE0N4O8m2uIs4duakF-fGpxQWJyal5qSbyzo5GZuamRpaGzMWEVACHdK5I</recordid><startdate>20170523</startdate><enddate>20170523</enddate><creator>SVENSSON, ROZANA</creator><creator>OVERGAARD, RUNE VIIG</creator><creator>WAGTMANN, PETER ANDREAS NICOLAI REUMERT</creator><creator>SVENDSEN, IVAN</creator><creator>ALIFRANGIS, LENE HJORTH</creator><scope>EVB</scope></search><sort><creationdate>20170523</creationdate><title>KILLER IG-LIKE RECEPTOR (KIR) ANTIBODIES, FORMULATIONS, AND USES THEREOF</title><author>SVENSSON, ROZANA ; OVERGAARD, RUNE VIIG ; WAGTMANN, PETER ANDREAS NICOLAI REUMERT ; SVENDSEN, IVAN ; ALIFRANGIS, LENE HJORTH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA2675291C3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2017</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SVENSSON, ROZANA</creatorcontrib><creatorcontrib>OVERGAARD, RUNE VIIG</creatorcontrib><creatorcontrib>WAGTMANN, PETER ANDREAS NICOLAI REUMERT</creatorcontrib><creatorcontrib>SVENDSEN, IVAN</creatorcontrib><creatorcontrib>ALIFRANGIS, LENE HJORTH</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SVENSSON, ROZANA</au><au>OVERGAARD, RUNE VIIG</au><au>WAGTMANN, PETER ANDREAS NICOLAI REUMERT</au><au>SVENDSEN, IVAN</au><au>ALIFRANGIS, LENE HJORTH</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>KILLER IG-LIKE RECEPTOR (KIR) ANTIBODIES, FORMULATIONS, AND USES THEREOF</title><date>2017-05-23</date><risdate>2017</risdate><abstract>Inhibitory Killer lg-Like Receptors (KIRs) on NK cells inhibit the activation of NK cell cytotoxicity required to clear cancer cells and other diseased cells in a subject. An IgG4 isotype anti-KIR antibody (1-7F9) overcomes the KIR-mediated inhibition of NK cell activation and, thus, potentiates NK cell-mediated cytotoxicity. The pharmacokinetics and pharmacodynamics of 1-7F9 is assessed in pre-clinical and clinical trials in order to determine a dosing frequency that is effective to potentiate NK cell cytotoxicity (i.e., modulate NK cells and/or treat cancer).
L'invention porte sur un nouvel anticorps anti-KIR isotype IgG4, sur de nouvelles formulations de celui-ci et d'autres anticorps anti-KIR IgG4, et sur des procédés d'utilisation de telles formulations. L'invention porte également sur des compositions, des formulations, des dosages et des régimes d'administration appropriés pour une activation des lymphocytes NK et des applications thérapeutiques d'anticorps anti-KIR, ainsi que sur des coffrets comprenant un ou plusieurs anticorps anti-KIR avec des instructions pour une utilisation dans le traitement du cancer.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA2675291C |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | KILLER IG-LIKE RECEPTOR (KIR) ANTIBODIES, FORMULATIONS, AND USES THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T21%3A41%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SVENSSON,%20ROZANA&rft.date=2017-05-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA2675291C%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |